Alessandra Di Bacco
0000-0003-2072-8712
3 papers found
Refreshing results…
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation
c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma
Missing publications? Search for publications with a matching author name.